Evonik Venture Capital
GermanyKey facts
Recent exits
No exits recorded yet.
Coverage notes
0 funds tracked, 0 portfolio companies (0 active · 0 realized). Verified weekly from public filings and deal announcements.
About Evonik Venture Capital
Evonik Venture Capital is the corporate venture capital arm of Evonik Industries with €400 million of fund volume as of December 2024, headquartered in Essen, Germany with offices in the USA and China. The firm was founded in 2012 as the corporate venture capital arm of the Evonik Industries specialty chemicals group and operates as a wholly-owned subsidiary with 50 plus direct and fund investments since 2012.
Investment thesis
Evonik Venture Capital deploys capital through a single €400 million evergreen-style corporate vehicle, targeting early-stage to growth-stage direct equity plus fund-of-funds commitments with up to €15 million per portfolio company. The strategy invests to give a global specialty-chemicals corporate early access to sustainability and decarbonisation technologies adjacent to its core business. Sector focus spans advanced precision biosolutions, energy transition, circular economy, smart and new materials, nutrition and care and specialty additives. Geographic deployment spans Germany, USA and China with European and North American deal focus.
Recent activity
Recent realised exits include materials and biotech (2023, most recent on record). Recent acquisitions include CircumFix (medtech Series A, 2024) plus two new portfolio investments completed in 2024. The platform continues active deployment across the strategic specialty-chemicals venture thesis. Detailed buyer names and multiple data available on Pro at €49/month.
Similar firms
Other private equity firms tracked on GP Intel.
See the full fund history.
Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.
Already a member? Sign in